Galapagos NV ADR GLPG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $28.54
- Day Range
- $28.98–29.46
- 52-Week Range
- $24.16–42.46
- Bid/Ask
- $29.36 / $29.44
- Market Cap
- $1.94 Bil
- Volume/Avg
- 76,509 / 151,910
Key Statistics
- Price/Earnings (Normalized)
- 141.23
- Price/Sales
- 6.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients’ lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,123
- Website
- https://www.glpg.com
Comparables
Valuation
|
Metric
|
GLPG
|
EXEL
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | 141.23 | 17.20 | — |
Price/Book Value | 0.62 | 3.53 | 4.47 |
Price/Sales | 6.88 | 4.01 | 4,373.22 |
Price/Cash Flow | 7.49 | 16.42 | — |
Price/Earnings
GLPG
EXEL
VRDN
Financial Strength
|
Metric
|
GLPG
|
EXEL
|
VRDN
|
|---|---|---|---|
Quick Ratio | 9.68 | 4.05 | 15.54 |
Current Ratio | 10.05 | 4.27 | 15.82 |
Interest Coverage | −53.31 | — | −92.88 |
Quick Ratio
GLPG
EXEL
VRDN
Profitability
|
Metric
|
GLPG
|
EXEL
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | 0.72% | 14.82% | −34.35% |
Return on Equity (Normalized) | 1.14% | 19.05% | −64.16% |
Return on Invested Capital (Normalized) | −1.42% | 14.99% | −41.62% |
Return on Assets
GLPG
EXEL
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tvrbmmqf | Yqdgj | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gzlthtkq | Bxtxfrc | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zptcmfsv | Dsbfwl | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Sygyjvgn | Rrqrqc | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Wkfytccw | Mlgkw | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ynvwhztp | Bygt | $28.0 Bil | |||
| Moderna Inc
MRNA
| Tgtkhmqz | Klpjs | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Htbsgnc | Ylnz | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nskxpjm | Mmzwqx | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tckphzqyv | Hmfrz | $12.6 Bil |
United States